Abstract:Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into anti-tumor N1 and pro-tumor N2 subsets. One of the major mechanisms underlying the tumor-promoting function of N2-TANs is suppression of adaptive immune cells, in particular, cytotoxic T lymphocytes. Currently, no established methodologies are available that can unequivocally distinguish immunosuppressive TANs and granulocytic/polymorphonuclear myeloid-derived suppressor cells (G/PMN-MDSC). In view of the critical role of PMN-MDSCs in immune evasion and resistance to cancer immunotherapy, as established from data obtained with diverse cancer models, therapeutic strategies targeting these cells have been actively developed to enhance the efficacy of immunotherapy. Here, we have reviewed the available literature on strategies targeting PMN-MDSCs and summarized the findings into four categories: (1) depletion of existing PMN-MDSCs, (2) blockade of the development of PMN-MDSCs, (3) blockade of PMN-MDSC recruitment, (4) inhibition of immunosuppressive function. Owing to their high mobility to inflamed organs and ability to trespass the blood-brain barrier, neutrophils are outstanding candidate carriers in nanoparticle-based therapies. Another attractive application of neutrophils in cancer therapy is the use of neutrophil membrane-derived nanovesicles as a surrogate of extracellular vesicles for more efficient and scalable drug delivery. In the second part of the review, we have highlighted recent advances in the field of neutrophil-based cancer drug delivery. Overall, we believe that neutrophil-based therapeutics are a rapidly growing area of cancer therapy with significant potential benefits.

An EPR-Independent Extravasation Strategy: Deformable Leukocytes As Vehicles for Improved Solid Tumor Therapy.

Strategies to Enhance Drug Delivery to Solid Tumors by Harnessing the EPR Effects and Alternative Targeting Mechanisms

Leukocyte-derived Biomimetic Nanoparticulate Drug Delivery Systems for Cancer Therapy

Selective Enhancing Blood Flow in Solid Tumor Tissue Is the Key for Achieving Satisfactory Delivery and Therapeutic Outcome of Nanodrugs via the EPR Effect

Transcytosis-enabled active extravasation of tumor nanomedicine.

Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect.

The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives.

The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application

Transcytosis-inducing biomaterials for actively translocating nanomedicines

Stromal Barriers and Strategies for the Delivery of Nanomedicine to Desmoplastic Tumors

Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy.

Leukocyte-based delivery systems for enhanced nanotheranostics of inflammation and cancer

Strategies to improve the EPR effect: A mechanistic perspective and clinical translation

Radial Extracorporeal Shock Wave Promotes the Enhanced Permeability and Retention Effect to Reinforce Cancer Nanothermotherapeutics

Targeting and Exploitation of Tumor-Associated Neutrophils to Enhance Immunotherapy and Drug Delivery for Cancer Treatment

Deformable nanocarriers for enhanced drug delivery and cancer therapy

The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy

Independent Of Epr Effect: A Smart Delivery Nanosystem For Tracking And Treatment Of Nonvascularized Intra-Abdominal Metastases

Enhancing Drug Penetration in Solid Tumors Via Nanomedicine: Evaluation Models, Strategies and Perspectives

Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery

New-generation Cytopharmaceuticals with Powerfully Boosted Extravasation for Enhanced Cancer Therapy.